Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, anxiety, loss of consciousness, and contraction or jerking of body muscles.
The Epilepsy Drugs in Development market research report provides an overview of the Epilepsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.
Epilepsy Pipeline Drugs Market Targets
The targets of the epilepsy pipeline drugs market are Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Voltage Gated Sodium Channel, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Potassium Voltage Gated Channel Subfamily KQT Member 2, Potassium Voltage Gated Channel Subfamily KQT Member 3, Sodium Channel Protein Type 8 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, 5-Hydroxytryptamine Receptor, and Serine/Threonine Protein Kinase mTOR.
Epilepsy pipeline drugs market, by targets
For more target insights, download a free report sample
Mechanisms of Action of Epilepsy Pipeline Drugs Market
The mechanisms of action of the epilepsy pipeline drugs market are Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Voltage Gated Sodium Channel Blocker, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Potassium Voltage Gated Channel Subfamily KQT Member 2 Activator, Potassium Voltage Gated Channel Subfamily KQT Member 3 Activator, Sodium Channel Protein Type 1 Subunit Alpha Activator, Sodium Channel Protein Type 8 Subunit Alpha Blocker, 5-Hydroxytryptamine Receptor Agonist, and Serine/Threonine Protein Kinase mTOR Inhibitor.
Epilepsy pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
Routes of Administration in Epilepsy Pipeline Drugs Market
The routes of administration in the epilepsy pipeline drugs market are oral, intravenous, subcutaneous, nasal, intrathecal, buccal, inhalational, sublingual, transdermal, and parenteral.
Epilepsy pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Molecule Types in Epilepsy Pipeline Drugs Market
The molecule types in the epilepsy pipeline drugs market are small molecule, antisense oligonucleotide, gene therapy, synthetic peptide, cell therapy, RNAi gene therapy, antibody, antisense RNAi oligonucleotide, biologic, and fusion protein.
Epilepsy pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Key Epilepsy Pipeline Drugs Market Companies
Some of the key companies in the epilepsy pipeline drugs market are Praxis Precision Medicines Inc, EpyGenix Therapeutics Inc, Neurocrine Biosciences Inc, Bio-Pharm Solutions Co Ltd, Q-State Biosciences Inc, Taysha Gene Therapies Inc, UCB SA, Jazz Pharmaceuticals Plc, SK Biopharmaceuticals Co Ltd, and AfaSci Inc.
Epilepsy pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
| Targets | Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Voltage Gated Sodium Channel, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Potassium Voltage Gated Channel Subfamily KQT Member 2, Potassium Voltage Gated Channel Subfamily KQT Member 3, Sodium Channel Protein Type 8 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, 5-Hydroxytryptamine Receptor, and Serine/Threonine Protein Kinase mTOR |
| Mechanisms of Action | Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Voltage Gated Sodium Channel Blocker, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Potassium Voltage Gated Channel Subfamily KQT Member 2 Activator, Potassium Voltage Gated Channel Subfamily KQT Member 3 Activator, Sodium Channel Protein Type 1 Subunit Alpha Activator, Sodium Channel Protein Type 8 Subunit Alpha Blocker, 5-Hydroxytryptamine Receptor Agonist, and Serine/Threonine Protein Kinase mTOR Inhibitor |
| Routes of Administration | Oral, Intravenous, Subcutaneous, Nasal, Intrathecal, Buccal, Inhalational, Sublingual, Transdermal, and Parenteral |
| Molecule Types | Small Molecule, Antisense Oligonucleotide, Gene Therapy, Synthetic Peptide, Cell Therapy, RNAi Gene Therapy, Antibody, Antisense RNAi Oligonucleotide, Biologic, and Fusion Protein |
| Key Companies | Praxis Precision Medicines Inc, EpyGenix Therapeutics Inc, Neurocrine Biosciences Inc, Bio-Pharm Solutions Co Ltd, Q-State Biosciences Inc, Taysha Gene Therapies Inc, UCB SA, Jazz Pharmaceuticals Plc, SK Biopharmaceuticals Co Ltd, and AfaSci Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
- Reviews of pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Epilepsy (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Epilepsy (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The targets of the epilepsy pipeline drugs market are Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Voltage Gated Sodium Channel, Cannabinoid Receptor 2, Cannabinoid Receptor 1, Potassium Voltage Gated Channel Subfamily KQT Member 2, Potassium Voltage Gated Channel Subfamily KQT Member 3, Sodium Channel Protein Type 8 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, 5-Hydroxytryptamine Receptor, and Serine/Threonine Protein Kinase mTOR.
The mechanisms of action of the epilepsy pipeline drugs market are Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAgonist, Voltage Gated Sodium Channel Blocker, Cannabinoid Receptor 2 Agonist, Cannabinoid Receptor 1 Agonist, Potassium Voltage Gated Channel Subfamily KQT Member 2 Activator, Potassium Voltage Gated Channel Subfamily KQT Member 3 Activator, Sodium Channel Protein Type 1 Subunit Alpha Activator, Sodium Channel Protein Type 8 Subunit Alpha Blocker, 5-Hydroxytryptamine Receptor Agonist, and Serine/Threonine Protein Kinase mTOR Inhibitor.
The routes of administration in the epilepsy pipeline drugs market are oral, intravenous, subcutaneous, nasal, intrathecal, buccal, inhalational, sublingual, transdermal, and parenteral.
The molecule types in the epilepsy pipeline drugs market are small molecule, antisense oligonucleotide, gene therapy, synthetic peptide, cell therapy, RNAi gene therapy, antibody, antisense RNAi oligonucleotide, biologic, and fusion protein.
Some of the key companies in the epilepsy pipeline drugs market are Praxis Precision Medicines Inc, EpyGenix Therapeutics Inc, Neurocrine Biosciences Inc, Bio-Pharm Solutions Co Ltd, Q-State Biosciences Inc, Taysha Gene Therapies Inc, UCB SA, Jazz Pharmaceuticals Plc, SK Biopharmaceuticals Co Ltd, and AfaSci Inc.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Central Nervous System reports